大和降康方生物(09926-HK)目标价至58.6港元 股价现跌7.34%

财华社
03 Mar 2021

原标题:大和降康方生物(09926-HK)目标价至58.6港元 股价现跌7.34%

   大和降康方生物(09926-HK)目标价至58.6港元及评级。康方生物近日公布,公司中国生物制药(01177-HK)共同开发的抗PD-1单抗药物派安普利(安尼可)(研发代号:AK105)联合紫杉醇和卡铂用于局部晚期或转移性鳞状非小细胞肺癌一线治疗的III期临床试验中期分析,达到主要研究终点。

  该公司股价现报49.25港元,跌7.34%,成交量133.90万,成交额6745.03万港元。

(文章来源:财华社)

(责任编辑:DF545)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10